Polpharma Biologics

We care about creating quality biologics with passion.

[Polpharma Biologics @PolpharmaB]

Very busy second day of #cphi2021. Many fruitful discussions and new opportunities identified. Thank you to everyone who visited our booth. We are still here today!
Meet us at booth 4G60
#polpharmabiologics #cphiworldwide #cphimilan
https://t.co/WSjBK4zJHO

[Polpharma Biologics @PolpharmaB]

Congratulations to the team for winning the 2021 Bioprocessing Excellence Award for Central and Eastern Europe.

The award acknowledges Polpharma Biologics' excellence in optimising processes for biosimilars that reduce downstream costs without impacting quality.

[Polpharma Biologics @PolpharmaB]

Dr Louis Boon at the Biologics Contract Manufacturing Europe conference 27th October:

9.00AM Plenary Panel: COVID-19's Impact On Contract Manufacturing

2.45PM Use Of Single-Use Bioreactor In The Development Of Biosimilar Monoclonal Antibodies

https://t.co/qe05P1rnK9

[Polpharma Biologics @PolpharmaB]

Polpharma Biologics Alexandra Moulson and Paweł Lewiński recently sat down to speak with Tony Hagen, senior editor of The Center for Biosimilars®, about our product expectations and growth.

https://t.co/pfFKTjH5EH

#biologics #wecare #biosimilars

[Polpharma Biologics @PolpharmaB]

Thank you to everyone who joined our recent webinar "Working in the Polish Biotech sector, why it is not what you think!"

In case you missed it, or if you simply want to review what was covered, you can rewatch it below.

https://t.co/pNFmZ2NPaQ

#biotech #webinar #wecare

[Polpharma Biologics @PolpharmaB]

Find out more about our attractive pipeline of globally available biosimilars at CPhI Worldwide.

To discuss partnering opportunities please visit stand 4G60 in the bioproduction zone or email us at [email protected] to arrange a meeting.

#cphiworldwide #wecare

[Polpharma Biologics @PolpharmaB]

Polpharma Biologics Group announces that the Biologics License Application (BLA) submitted by its joint venture Bioeq for its biosimilar Ranibizumab has been accepted for review by the U.S. Food and Drug Administration (FDA)

https://t.co/hcw6YhqVSW

#wecare #fda #biosimilars

[Polpharma Biologics @PolpharmaB]

Don’t miss out. Register today to watch this webinar where we will explore why working in the Polish Biotech sector may be different to what you might think.

https://t.co/ryDOcVD0OE

#biotech #careersearch #biotechnology #wecare

[Polpharma Biologics @PolpharmaB]

Polpharma Biologics announces 70 new vacancies as the rapid growth of the Polish biotechnology sector leads to demand for foreign expertise.

To view the vacancies, visit: https://t.co/dI0w3KqoD1

To read the press release, visit: https://t.co/goiUd19nIE

#biotechnology #jobs

[Polpharma Biologics @PolpharmaB]

At Polpharma Biologics we took action to implement a workplace COVID-19 vaccination program for all our employees. Thanks to this, we feel even safer in our company and can do what we are passionate about - helping others.

#wecare #wevaccinate #polpharmabiologics

[Polpharma Biologics @PolpharmaB]

At Polpharma Biologics we are developing a biosimilar portfolio and pipeline focused on increasing patient access to much needed therapies.

We are looking for specialists across biotech to join our team, see our vacancies here: https://t.co/dI0w3KqoD1

#biotech #wecare

[Polpharma Biologics @PolpharmaB]

We are excited to announce that our joint venture Bioeq has submitted a biologics license application for biosimilar Ranibizumab to the FDA.

Read the full press release here: https://t.co/W0ikGhKjd4

[Polpharma Biologics @PolpharmaB]

Positive news for the progress of Polpharma Biologics biosimilar natalizumab.
The Opposition Division of the EPO has revoked a Biogen patent covering the treatment for relapsing-remittent multiple sclerosis.
You can read the full story on JUVE patent https://t.co/QCogjYHM5s

[Polpharma Biologics @PolpharmaB]

Bioeq, spółka JV Grupy Polpharma Biologics i Santo Holding, nawiązała partnerstwo z liderem farmaceutycznym Teva Pharmaceuticals na komercjalizację leku biopodobnego do Ranibizumabu stosowanego w terapii okulistycznej. Współpraca dotyczy Europy, Kanady, Izraela i Nowej Zelandii

[Polpharma Biologics @PolpharmaB]

We are excited to announce the creation of a new development team, bringing together the functions of technical development, regulatory affairs, clinical development, IP, program management, portfolio and launch. The new group will be led by Alex Moulson, VP of Development.

[Polpharma Biologics @PolpharmaB]

Polpharma Biologics’ COO, Jan Krzewiński has been speaking at the Forum for Health Dialogue today:

[Polpharma Biologics @PolpharmaB]

Polpharma Biologics’ COO, Jan Krzewiński is speaking at the Forum for Health Dialogue:

[Polpharma Biologics @PolpharmaB]

Jan Krzewiński, Prezes Polpharma Biologics Gdańsk, uczestniczy w Forum Dialogu dla Zdrowia:

[Polpharma Biologics @PolpharmaB]

Polpharma Biologics’ COO, Jan K Krzewiński is speaking at the Forum for Health Dialogue:

[Polpharma Biologics @PolpharmaB]

Jan Krzewiński, Prezes Polpharma Biologics Gdańsk, uczestniczy w Forum Dialogu dla Zdrowia: